Assembly Biosciences, Inc. (ASMB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 24.44 |
| Open | 24.5 |
| Day High | 26.14 |
| Day Low | 24.44 |
| 52-Week High | 39.71 |
| 52-Week Low | 16.81 |
| Volume | 267,628 |
| Average Volume | 152,246 |
| Market Cap | 399.71M |
| PE | 314.38 |
| EPS | 0.08 |
| Moving Average 50 Days | 27.09 |
| Moving Average 200 Days | 28.89 |
| Change | 0.71 |
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
GlobeNewswire Inc.
Nov 07, 2025 1:00 PM GMT
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Bioscien
Assembly Biosciences Announces Upcoming Investor Conference Participation
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
GlobeNewswire Inc.
Oct 10, 2025 12:00 PM GMT
– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rat